Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Eveslage

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Zeitschrift Fur Rheumatologie|March 26, 2015
[Modern study designs and analysis methods in clinical research]J Gerß, M Eveslage, A Faldum, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 14, 2017
PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survivalK Rahbar, M Boegemann, A Yordanova, et al.
Annals of the Rheumatic Diseases|July 28, 2011
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?A Strangfeld, M Eveslage, M Schneider, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 23, 2019
Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysisC Weishaupt, A Strölin, B Kahle, et al.
Leukemia|November 3, 2015
Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance LeukemiaC Müller-Tidow, P Tschanter, C Röllig, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Zeitschrift Fur Rheumatologie|March 26, 2015
[Modern study designs and analysis methods in clinical research]J Gerß, M Eveslage, A Faldum, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 14, 2017
PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survivalK Rahbar, M Boegemann, A Yordanova, et al.
Annals of the Rheumatic Diseases|July 28, 2011
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?A Strangfeld, M Eveslage, M Schneider, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 23, 2019
Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysisC Weishaupt, A Strölin, B Kahle, et al.
Leukemia|November 3, 2015
Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance LeukemiaC Müller-Tidow, P Tschanter, C Röllig, et al.
Pageof 1